<--- Back to Details
First PageDocument Content
Monoclonal antibodies / Autoimmune diseases / Biotechnology / Immunosuppressants / Immunology / TNF inhibitor / Rheumatology / Adalimumab / Infliximab / Arthritis / Disease-modifying antirheumatic drug / Rheumatoid arthritis
Date: 2015-06-19 09:15:29
Monoclonal antibodies
Autoimmune diseases
Biotechnology
Immunosuppressants
Immunology
TNF inhibitor
Rheumatology
Adalimumab
Infliximab
Arthritis
Disease-modifying antirheumatic drug
Rheumatoid arthritis

TABLE OF CONTENTS INTRODUCTION 2

Add to Reading List

Source URL: www.abirisk.eu

Download Document from Source Website

File Size: 901,09 KB

Share Document on Facebook

Similar Documents

KICK-OFF MEETING 1st-3rd October 2013 Kennedy Institute Of Rheumatology, Roosevelt Drive, Headington - Oxford, OX3 7FY - UK

DocID: 1vpYJ - View Document

10th Orthopedics & Rheumatology Annual Meeting & Expo Aug 31-Sept 1, 2018 Toronto | Ontario | Canada Tentative Program

DocID: 1vnha - View Document

Selected Topics in Clinical Immunology - BiologicsBiomedical Sciences March 1, 2018 S. Adler RIA Department of Rheumatology, Immunology and Allergology

DocID: 1v3Pj - View Document

A N N U A L M E E T I N G 28th-29th SeptemberKennedy Institute of Rheumatology - Oxford - UK LIST OF PARTICIPANTS

DocID: 1uKoJ - View Document

Reprinted from: The Journal of the Canadian Rheumatology Association / Volume 28, Number 1, Spring 2018, ppJOINT COMMUNIQUÉ Models of Care: The International Perspective

DocID: 1ujSW - View Document